title: Autologous activated macrophages (MAK) coated ex vivo with humanized anti-CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response.
authors.forename: Laurent
authors.initials: L
authors.lastname: Sutton
authors.forename: Driss
authors.initials: D
authors.lastname: Chaoui
authors.forename: Bruno
authors.initials: B
authors.lastname: Cazin
authors.forename: Nabih
authors.initials: N
authors.lastname: Azar
authors.forename: Mohamed
authors.initials: M
authors.lastname: Chokri
authors.forename: Jean-Loup
authors.initials: JL
authors.lastname: Romet-Lemonne
authors.forename: Karim
authors.initials: K
authors.lastname: Maloum
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008262:Macrophage Activation; D008264:Macrophages / Q000637:transplantation*; D018365:Neoplasm, Residual; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab